|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Avenue Therapeutics, Inc. (ATXI) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
16,750,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Avenue Therapeutics is a pharmaceutical company that develop and commercialize its product principally for use in the acute/intensive care hospital setting. Co.'s product candidate is intravenous (IV) Tramadol, for the treatment of post-operative acute pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Co. has completed a pharmacokinetic study for IV Tramadol in healthy volunteers. Co. also has initiated a Phase 3 development program of IV Tramadol for the management of post-operative pain.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
767,085 |
767,085 |
| Total Buy Value |
$0 |
$0 |
$552,301 |
$552,301 |
| Total People Bought |
0 |
0 |
2 |
2 |
| Total Buy Transactions |
0 |
0 |
2 |
2 |
| Total Shares Sold |
0 |
617,000 |
617,000 |
1,005,888 |
| Total Sell Value |
$0 |
$86,560 |
$86,560 |
$3,086,442 |
| Total People Sold |
0 |
1 |
1 |
2 |
| Total Sell Transactions |
0 |
2 |
2 |
3 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Herskowitz Neil |
Director |
– • – |
2020-02-25 |
4 |
B |
$9.31 |
$93,100 |
D/D |
10,000 |
119,663 |
2.39 |
- |
|
| Vazzano Joseph Walter |
Chief Financial Officer |
• – – |
2020-02-25 |
4 |
B |
$9.09 |
$10,908 |
D/D |
1,200 |
57,863 |
2.74 |
- |
|
| Ingram Elizabeth Garrett |
Director |
– • – |
2019-09-12 |
4 |
B |
$6.27 |
$100,320 |
D/D |
16,000 |
16,000 |
2.39 |
- |
|
| Herskowitz Neil |
Director |
– • – |
2019-08-27 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
109,663 |
|
- |
|
| Kranzler Jay D |
Director |
– • – |
2019-08-27 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
74,663 |
|
- |
|
| Vazzano Joseph Walter |
Chief Financial Officer |
• – – |
2019-08-09 |
4 |
S |
$5.56 |
$13,205 |
D/D |
(2,375) |
56,663 |
|
- |
|
| Vazzano Joseph Walter |
Chief Financial Officer |
• – – |
2019-08-08 |
4 |
S |
$5.62 |
$12,999 |
D/D |
(2,313) |
59,038 |
|
- |
|
| Herskowitz Neil |
Director |
– • – |
2019-06-18 |
4 |
B |
$5.83 |
$11,660 |
D/D |
2,000 |
99,663 |
2.39 |
- |
|
| Herskowitz Neil |
Director |
– • – |
2019-06-17 |
4 |
B |
$5.88 |
$17,640 |
D/D |
3,000 |
97,663 |
2.39 |
- |
|
| Herskowitz Neil |
Director |
– • – |
2019-04-15 |
4 |
B |
$4.52 |
$4,520 |
D/D |
1,000 |
94,663 |
2.31 |
- |
|
| Herskowitz Neil |
Director |
– • – |
2019-03-29 |
4 |
B |
$5.11 |
$7,154 |
D/D |
1,400 |
93,663 |
2.39 |
- |
|
| Herskowitz Neil |
Director |
– • – |
2019-03-28 |
4 |
B |
$5.11 |
$3,066 |
D/D |
600 |
92,263 |
2.31 |
- |
|
| Herskowitz Neil |
Director |
– • – |
2019-02-25 |
4 |
B |
$5.46 |
$27,300 |
D/D |
5,000 |
91,663 |
2.39 |
- |
|
| Invagen Pharmaceuticals, Inc. |
|
– – • |
2019-02-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
250,000 |
|
- |
|
| Invagen Pharmaceuticals, Inc. |
|
– – • |
2019-02-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,923,429 |
|
- |
|
| Invagen Pharmaceuticals, Inc. |
|
– – • |
2019-02-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,833,333 |
|
- |
|
| Herskowitz Neil |
Director |
– • – |
2019-02-05 |
4 |
B |
$5.77 |
$10,675 |
D/D |
1,850 |
86,663 |
2.39 |
- |
|
| Herskowitz Neil |
Director |
– • – |
2019-02-04 |
4 |
B |
$5.91 |
$41,370 |
D/D |
7,000 |
84,813 |
2.39 |
- |
|
| Herskowitz Neil |
Director |
– • – |
2019-01-30 |
4 |
B |
$5.91 |
$3,842 |
D/D |
650 |
77,813 |
2.31 |
- |
|
| Herskowitz Neil |
Director |
– • – |
2019-01-29 |
4 |
B |
$5.91 |
$50,548 |
D/D |
8,553 |
77,163 |
2.39 |
- |
|
| Herskowitz Neil |
Director |
– • – |
2019-01-28 |
4 |
B |
$5.84 |
$8,450 |
D/D |
1,447 |
68,610 |
2.39 |
- |
|
| Paley Jeffrey |
Director |
– • – |
2018-12-10 |
4 |
B |
$4.76 |
$23,800 |
D/D |
5,000 |
79,663 |
2.39 |
- |
|
| Paley Jeffrey |
Director |
– • – |
2018-12-03 |
4 |
B |
$5.48 |
$54,754 |
D/D |
10,000 |
74,663 |
2.39 |
- |
|
| Kranzler Jay D |
Director |
– • – |
2018-08-07 |
4 |
GA |
$0.00 |
$0 |
D/D |
14,663 |
64,663 |
|
- |
|
| Vazzano Joseph Walter |
VP Finance & Corp. Controller |
• – – |
2018-08-07 |
4 |
GA |
$0.00 |
$0 |
D/D |
30,000 |
61,351 |
|
- |
|
85 Records found
|
|
Page 2 of 4 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
